16 assets in Female Reproductive System Neoplasm

Therapeutic assets addressing Female Reproductive System Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Female Reproductive System Neoplasm	Wenjun Cheng	P3	BB (68)
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Female Reproductive System Neoplasm	Sichuan Cancer Hospital and Research Institute	P3	BB (64)
Pembrolizumab Female Reproductive System Neoplasm	Sheba Medical Center	P2	B (60)
Nilotinib Female Reproductive System Neoplasm	National Cancer Institute (NCI)	P2	B (57)
Catequentinib Female Reproductive System Neoplasm	Wenjun Cheng	P2	CCC (53)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) Female Reproductive System Neoplasm	Liu Zi	P2	CCC (53)
Ipilimumab Female Reproductive System Neoplasm	Olivia Newton-John Cancer Research Institute	P2	CCC (53)
Lenvatinib Female Reproductive System Neoplasm	Sheba Medical Center	P2	CCC (53)
Nivolumab Female Reproductive System Neoplasm	Olivia Newton-John Cancer Research Institute	P2	CCC (53)
Dostarlimab Female Reproductive System Neoplasm	GlaxoSmithKline	P1/2	CCC (48)
Mo-Rez Female Reproductive System Neoplasm	GlaxoSmithKline	P1/2	CCC (48)
Star0602 Female Reproductive System Neoplasm	Marengo Therapeutics, Inc.	P1/2	CCC (48)
ab-1015 Female Reproductive System Neoplasm	Arsenal Biosciences, Inc.	P1	CC (43)
Atv-1601 Female Reproductive System Neoplasm	Atavistik Bio, Inc	P1	CC (43)
Fulvestrant Female Reproductive System Neoplasm	Atavistik Bio, Inc	P1	CC (43)
gt316 Female Reproductive System Neoplasm	Grit Biotechnology	N/A	D (30)